Globus Medical (GMED) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.34
- EPS estimate
- $1.10
- EPS surprise
- +21.92%
- Revenue surprise
- +0.86%
- Revenue
- $789.6M
- Revenue estimate
- $782.9M
- Reported
- Aug 6, 2026
Globus Medical reported Q2 2026 results on August 6, 2026. Earnings per share were $1.34, ahead of the $1.10 estimate by 21.92% and the highest in the table. Revenue was $789.6 million, 0.86% above the $782.9 million consensus. Compared with Q2 2025, EPS rose about 56% from $0.86 and revenue rose about 5.9% from $745.3 million.
Annual EPS grew from $2.07 in 2022 to $2.33 in 2023, $3.14 in 2024 and $4.00 in 2025. The first half of 2026 adds up to $2.46 per share, about 60% more than the $1.54 of the first half of 2025. Quarterly revenue stepped up from $383.6 million in Q3 2023 to $616.5 million in Q4 2023 and has stayed at $598 million or more since, peaking at $826.4 million in Q4 2025. Globus Medical beat the EPS estimate 17 times. Its largest beat was 51.13% in Q3 2025.
The company reported its third quarter between November 4 and November 8 in each of the past five years. That points to early November 2026 for the Q3 2026 report. It will show how results compare with Q3 2025's $1.18 per share and $769.0 million in revenue.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $1.10 | $1.34 | +21.92% | $789.6M | SEC |
| Q1 2026 | May 7, 2026 | $0.92 | $1.12 | +21.81% | $759.9M | SEC |
| Q4 2025 | Feb 24, 2026 | $1.13 | $1.28 | +12.88% | $826.4M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.78 | $1.18 | +51.13% | $769.0M | SEC |
| Q2 2025 | Aug 7, 2025 | $0.75 | $0.86 | +14.19% | $745.3M | SEC |
| Q1 2025 | May 8, 2025 | $0.74 | $0.68 | −8.60% | $598.1M | SEC |
| Q4 2024 | Feb 20, 2025 | $0.75 | $0.84 | +12.36% | $657.3M | SEC |
| Q3 2024 | Nov 5, 2024 | $0.65 | $0.83 | +28.26% | $625.7M | SEC |
| Q2 2024 | Aug 6, 2024 | $0.68 | $0.75 | +10.72% | $629.7M | SEC |
| Q1 2024 | May 7, 2024 | $0.57 | $0.72 | +26.98% | $606.7M | SEC |
| Q4 2023 | Feb 20, 2024 | $0.58 | $0.60 | +2.70% | $616.5M | SEC |
| Q3 2023 | Nov 7, 2023 | $0.54 | $0.57 | +5.58% | $383.6M | SEC |
| Q2 2023 | Aug 3, 2023 | $0.59 | $0.63 | +6.67% | $291.6M | SEC |
| Q1 2023 | May 4, 2023 | $0.51 | $0.53 | +4.19% | $276.7M | SEC |
| Q4 2022 | Feb 21, 2023 | $0.56 | $0.59 | +5.39% | $274.5M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.52 | $0.50 | −3.42% | $254.1M | SEC |
| Q2 2022 | Aug 4, 2022 | $0.53 | $0.56 | +4.97% | $263.6M | SEC |
| Q1 2022 | May 10, 2022 | $0.47 | $0.42 | −10.20% | $230.5M | SEC |
| Q4 2021 | Feb 17, 2022 | $0.47 | $0.49 | +3.73% | $250.0M | SEC |
| Q3 2021 | Nov 4, 2021 | $0.45 | $0.50 | +10.72% | $229.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Globus Medical (GMED) last report earnings?
Globus Medical last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did GMED beat earnings estimates?
Yes. Globus Medical reported EPS of $1.34 for Q2 2026 against a $1.10 estimate — a 21.92% beat.
How much revenue did GMED report last quarter?
Globus Medical reported $789.6M in revenue for Q2 2026, against a consensus estimate of $782.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.